119 related articles for article (PubMed ID: 38266031)
1. Editorial Note: Immunomodulation Targeting Abnormal Protein Conformation Reduces Pathology in a Mouse Model of Alzheimer's Disease.
PLOS ONE Editors
PLoS One; 2024; 19(1):e0297928. PubMed ID: 38266031
[No Abstract] [Full Text] [Related]
2. Immunomodulation targeting abnormal protein conformation reduces pathology in a mouse model of Alzheimer's disease.
Goñi F; Prelli F; Ji Y; Scholtzova H; Yang J; Sun Y; Liang FX; Kascsak R; Kascsak R; Mehta P; Wisniewski T
PLoS One; 2010 Oct; 5(10):e13391. PubMed ID: 20967130
[TBL] [Abstract][Full Text] [Related]
3. Immunomodulation targeting of both Aβ and tau pathological conformers ameliorates Alzheimer's disease pathology in TgSwDI and 3xTg mouse models.
Goñi F; Herline K; Peyser D; Wong K; Ji Y; Sun Y; Mehta P; Wisniewski T
J Neuroinflammation; 2013 Dec; 10():150. PubMed ID: 24330773
[TBL] [Abstract][Full Text] [Related]
4. Vaccination as a therapeutic approach to Alzheimer's disease.
Wisniewski T; Boutajangout A
Mt Sinai J Med; 2010; 77(1):17-31. PubMed ID: 20101719
[TBL] [Abstract][Full Text] [Related]
5. Muramyl dipeptide-mediated immunomodulation on monocyte subsets exerts therapeutic effects in a mouse model of Alzheimer's disease.
Fani Maleki A; Cisbani G; Plante MM; Préfontaine P; Laflamme N; Gosselin J; Rivest S
J Neuroinflammation; 2020 Jul; 17(1):218. PubMed ID: 32698829
[TBL] [Abstract][Full Text] [Related]
6. Vaccines for Alzheimer's disease: how close are we?
Janus C
CNS Drugs; 2003; 17(7):457-74. PubMed ID: 12751917
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-2 improves amyloid pathology, synaptic failure and memory in Alzheimer's disease mice.
Alves S; Churlaud G; Audrain M; Michaelsen-Preusse K; Fol R; Souchet B; Braudeau J; Korte M; Klatzmann D; Cartier N
Brain; 2017 Mar; 140(3):826-842. PubMed ID: 28003243
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapeutic approaches for Alzheimer's disease in transgenic mouse models.
Wisniewski T; Boutajangout A
Brain Struct Funct; 2010 Mar; 214(2-3):201-18. PubMed ID: 20012091
[TBL] [Abstract][Full Text] [Related]
9. Long-term immunomodulatory effect of amniotic stem cells in an Alzheimer's disease model.
Kim KS; Kim HS; Park JM; Kim HW; Park MK; Lee HS; Lim DS; Lee TH; Chopp M; Moon J
Neurobiol Aging; 2013 Oct; 34(10):2408-20. PubMed ID: 23623603
[TBL] [Abstract][Full Text] [Related]
10. Neuroendocrine immunomodulation network dysfunction in SAMP8 mice and PrP-hAβPPswe/PS1ΔE9 mice: potential mechanism underlying cognitive impairment.
Wang JH; Cheng XR; Zhang XR; Wang TX; Xu WJ; Li F; Liu F; Cheng JP; Bo XC; Wang SQ; Zhou WX; Zhang YX
Oncotarget; 2016 Apr; 7(17):22988-3005. PubMed ID: 27049828
[TBL] [Abstract][Full Text] [Related]
11. Amyloid reduction by amyloid-beta vaccination also reduces mouse tau pathology and protects from neuron loss in two mouse models of Alzheimer's disease.
Wilcock DM; Gharkholonarehe N; Van Nostrand WE; Davis J; Vitek MP; Colton CA
J Neurosci; 2009 Jun; 29(25):7957-65. PubMed ID: 19553436
[TBL] [Abstract][Full Text] [Related]
12. Anti-β-sheet conformation monoclonal antibody reduces tau and Aβ oligomer pathology in an Alzheimer's disease model.
Goñi F; Martá-Ariza M; Herline K; Peyser D; Boutajangout A; Mehta P; Drummond E; Prelli F; Wisniewski T
Alzheimers Res Ther; 2018 Jan; 10(1):10. PubMed ID: 29378642
[TBL] [Abstract][Full Text] [Related]
13. Telomere shortening reduces Alzheimer's disease amyloid pathology in mice.
Rolyan H; Scheffold A; Heinrich A; Begus-Nahrmann Y; Langkopf BH; Hölter SM; Vogt-Weisenhorn DM; Liss B; Wurst W; Lie DC; Thal DR; Biber K; Rudolph KL
Brain; 2011 Jul; 134(Pt 7):2044-56. PubMed ID: 21672962
[TBL] [Abstract][Full Text] [Related]
14. Inositol trisphosphate 3-kinase B is increased in human Alzheimer brain and exacerbates mouse Alzheimer pathology.
Stygelbout V; Leroy K; Pouillon V; Ando K; D'Amico E; Jia Y; Luo HR; Duyckaerts C; Erneux C; Schurmans S; Brion JP
Brain; 2014 Feb; 137(Pt 2):537-52. PubMed ID: 24401760
[TBL] [Abstract][Full Text] [Related]
15. A multifunctional therapeutic approach to disease modification in multiple familial mouse models and a novel sporadic model of Alzheimer's disease.
Luo J; Lee SH; VandeVrede L; Qin Z; Ben Aissa M; Larson J; Teich AF; Arancio O; D'Souza Y; Elharram A; Koster K; Tai LM; LaDu MJ; Bennett BM; Thatcher GR
Mol Neurodegener; 2016 Apr; 11():35. PubMed ID: 27129593
[TBL] [Abstract][Full Text] [Related]
16. The Trem2 R47H Alzheimer's risk variant impairs splicing and reduces Trem2 mRNA and protein in mice but not in humans.
Xiang X; Piers TM; Wefers B; Zhu K; Mallach A; Brunner B; Kleinberger G; Song W; Colonna M; Herms J; Wurst W; Pocock JM; Haass C
Mol Neurodegener; 2018 Sep; 13(1):49. PubMed ID: 30185230
[TBL] [Abstract][Full Text] [Related]
17. Breaking immune tolerance by targeting Foxp3(+) regulatory T cells mitigates Alzheimer's disease pathology.
Baruch K; Rosenzweig N; Kertser A; Deczkowska A; Sharif AM; Spinrad A; Tsitsou-Kampeli A; Sarel A; Cahalon L; Schwartz M
Nat Commun; 2015 Aug; 6():7967. PubMed ID: 26284939
[TBL] [Abstract][Full Text] [Related]
18. PTI-125 Reduces Biomarkers of Alzheimer's Disease in Patients.
Wang HY; Pei Z; Lee KC; Lopez-Brignoni E; Nikolov B; Crowley CA; Marsman MR; Barbier R; Friedmann N; Burns LH
J Prev Alzheimers Dis; 2020; 7(4):256-264. PubMed ID: 32920628
[TBL] [Abstract][Full Text] [Related]
19. Peptide aptamer targeting Aβ-PrP-Fyn axis reduces Alzheimer's disease pathologies in 5XFAD transgenic mouse model.
Ali T; Klein AN; Vu A; Arifin MI; Hannaoui S; Gilch S
Cell Mol Life Sci; 2023 May; 80(6):139. PubMed ID: 37149826
[TBL] [Abstract][Full Text] [Related]
20. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease.
Janus C; Pearson J; McLaurin J; Mathews PM; Jiang Y; Schmidt SD; Chishti MA; Horne P; Heslin D; French J; Mount HT; Nixon RA; Mercken M; Bergeron C; Fraser PE; St George-Hyslop P; Westaway D
Nature; 2000 Dec 21-28; 408(6815):979-82. PubMed ID: 11140685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
